Review



sirt3 agonist honokiol  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    MedChemExpress sirt3 agonist honokiol
    Sirt3 Agonist Honokiol, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 80 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sirt3+agonist/Honokiol/pm42263892-56-39-42
    Average 95 stars, based on 80 article reviews
    sirt3 agonist honokiol - by Bioz Stars, 2026-10
    95/100 stars

    Images

    Related Articles

    Control:

    Article Title: Targeting SIRT3 to regulate mitophagy-dependent ferroptosis for preventing glucocorticoid-induced osteoporosis
    Article Snippet: .. A cohort of 40 male Sprague-Dawley rats (8-week-old, SPF-grade) were randomly allocated into four groups (n=10/group): Control: PBS vehicle Model: Glucocorticoids-induced osteoporosis (GIOP) Mdivi-1: GIOP + 15 mg/kg Mdivi-1 (MedChemExpress, HY-15886) i.p. every 48h(61) SIRT3 agonist: GIOP + 200 mg/kg nicotinamide riboside (MedChemExpress, HY- 15452) p.o. daily(62) After 4 weeks of intervention, rats were humanely euthanized and tibiae were harvested for analysis (n=5). ..

    Article Title: Targeting SIRT3 to regulate mitophagy-dependent ferroptosis for preventing glucocorticoid-induced osteoporosis
    Article Snippet: .. A cohort of 40 male Sprague-Dawley rats (8-week-old, SPF-grade) were randomly allocated into four groups (n = 10/group): Control: PBS vehicle Model: GIOP Mdivi-1: GIOP + 15 mg/kg Mdivi-1 (MedChemExpress, HY-15 886) i.p. every 48 h [ ] SIRT3 agonist: GIOP + 200 mg/kg nicotinamide riboside (MedChemExpress, HY-15 452) p.o. daily [ ] . ..



    Similar Products

    sirt3 agonist honokiol  (MedChemExpress)
    95
    MedChemExpress sirt3 agonist honokiol
    Sirt3 Agonist Honokiol, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sirt3+agonist/Honokiol/pm42263892-56-39-42
    Average 95 stars, based on 1 article reviews
    sirt3 agonist honokiol - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    natural sirt3 agonist  (TargetMol)
    93
    TargetMol natural sirt3 agonist
    Natural Sirt3 Agonist, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sirt3+agonist/Honokiol/pm36683245-321-15-20
    Average 93 stars, based on 1 article reviews
    natural sirt3 agonist - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    sirt3 agonist nicotinamide riboside chloride  (MedChemExpress)
    94
    MedChemExpress sirt3 agonist nicotinamide riboside chloride
    Sirt3 Agonist Nicotinamide Riboside Chloride, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sirt3+agonist/Nicotinamide+riboside+chloride/10__1016_slash_j__cej__2026__174938-208-3-9
    Average 94 stars, based on 1 article reviews
    sirt3 agonist nicotinamide riboside chloride - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    sirt3 agonist  (MedChemExpress)
    95
    MedChemExpress sirt3 agonist
    <t>SIRT3</t> suppresses mitophagy-dependent ferroptosis, restoring the osteogenic capacity of MC3T3-E1 cells. (A) Machine learning (LASSO/SVM-RFE/Random Forest) identified GIOP-mitophagy associated genes. (B) SIRT3 expression correlated with GIOP progression. (C) qRT-PCR quantified PINK1/PARKIN mRNA in DEX-treated cells. (D-E) Western blot detected PINK1/PARKIN protein in DEX/DEX + SIRT3 groups. (F) IF visualized SIRT3 alterations (DEX group, 50 μm). (G) Multiplex IF showed GPX4/TFR/PINK1/PARKIN/SIRT3 changes (DEX/DEX + SIRT3, 50 μm). (H-I) Osteogenic capacity assessed by ALP/ARS staining. (J-K) Oxidative stress markers (MDA/GSH) measured. (L) qPCR analyzed PINK1/PARKIN/RUNX2/OPG/SIRT3 expression. Experimental design: n =3 biological replicates (technical triplicates). Data: mean ± SD. Statistics: one-way ANOVA. (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001).
    Sirt3 Agonist, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sirt3+agonist/SIRT3%2C+Human/pmc12527695-212-38-46
    Average 95 stars, based on 1 article reviews
    sirt3 agonist - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    sirt3 agonist group  (MedChemExpress)
    95
    MedChemExpress sirt3 agonist group
    Fig. 5 SIRT3 exerts its regulatory role by modulating mitophagy. a Firstly, ferroptosis and mitochondria-related proteins were selected from public databases and intersected with the differentially expressed proteins obtained from bone slices of SIONFH patients. A total of 45 proteins were identified from patient samples. Finally, the key protein SIRT3 was determined using Lasso, random forest (RF), and support vector machine with recursive feature elimination (SVM-RFE) methods. b WB analysis of SIRT3 expression in MC3T3-E1 cells treated with DEX. c IF staining of SIRT3 expression in MC3T3-E1 cells treated with DEX. Scale bar = 50 μm. d Molecular docking was performed to predict the interaction between SIRT3 and BNIP3. e Co-IP was performed to investigate the interaction between SIRT3 and BNIP3. f Effect of <t>SIRT3</t> <t>agonist</t> on the proliferation of MC3T3-E1 cells was determined by CCK-8 assay after 2 days of stimulation. g Assessment of mitophagy levels using TEM after DEX and SIRT3 agonist intervention. For regular images, scale bar = 50 μm, and for magnified images, scale bar = 10 μm. h IF staining of SIRT3, BNIP3, NIX and DRP1 expression in MC3T3-E1 cells treated with DEX and SIRT3 agonist. Scale bar = 50 μm. i WB analysis of SIRT3, BNIP3, NIX, DRP1, MFN1 and MFN2 expression in MC3T3-E1 cells treated with DEX and SIRT3 agonist. j Flow cytometry analysis of ROS using MFI after DEX and SIRT3 agonist intervention. k The evaluation MMP was performed using JC-1 staining following DEX and SIRT3 agonist intervention. Scale bar = 200 μm. In the DEX + SIRT3 agonist group, 1 μmol/L DEX and 800 μmol/L SIRT3 agonist was added. The cell sample size is n = 3. Data were shown as mean ± SD. One-way ANOVA with Bonferroni multiple comparisons test was used for multiple comparisons. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.000 1
    Sirt3 Agonist Group, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sirt3+agonist/SIRT3%2C+Human/pm39865068-213-1-15
    Average 95 stars, based on 1 article reviews
    sirt3 agonist group - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    SIRT3 suppresses mitophagy-dependent ferroptosis, restoring the osteogenic capacity of MC3T3-E1 cells. (A) Machine learning (LASSO/SVM-RFE/Random Forest) identified GIOP-mitophagy associated genes. (B) SIRT3 expression correlated with GIOP progression. (C) qRT-PCR quantified PINK1/PARKIN mRNA in DEX-treated cells. (D-E) Western blot detected PINK1/PARKIN protein in DEX/DEX + SIRT3 groups. (F) IF visualized SIRT3 alterations (DEX group, 50 μm). (G) Multiplex IF showed GPX4/TFR/PINK1/PARKIN/SIRT3 changes (DEX/DEX + SIRT3, 50 μm). (H-I) Osteogenic capacity assessed by ALP/ARS staining. (J-K) Oxidative stress markers (MDA/GSH) measured. (L) qPCR analyzed PINK1/PARKIN/RUNX2/OPG/SIRT3 expression. Experimental design: n =3 biological replicates (technical triplicates). Data: mean ± SD. Statistics: one-way ANOVA. (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001).

    Journal: International Journal of Surgery (London, England)

    Article Title: Targeting SIRT3 to regulate mitophagy-dependent ferroptosis for preventing glucocorticoid-induced osteoporosis

    doi: 10.1097/JS9.0000000000002783

    Figure Lengend Snippet: SIRT3 suppresses mitophagy-dependent ferroptosis, restoring the osteogenic capacity of MC3T3-E1 cells. (A) Machine learning (LASSO/SVM-RFE/Random Forest) identified GIOP-mitophagy associated genes. (B) SIRT3 expression correlated with GIOP progression. (C) qRT-PCR quantified PINK1/PARKIN mRNA in DEX-treated cells. (D-E) Western blot detected PINK1/PARKIN protein in DEX/DEX + SIRT3 groups. (F) IF visualized SIRT3 alterations (DEX group, 50 μm). (G) Multiplex IF showed GPX4/TFR/PINK1/PARKIN/SIRT3 changes (DEX/DEX + SIRT3, 50 μm). (H-I) Osteogenic capacity assessed by ALP/ARS staining. (J-K) Oxidative stress markers (MDA/GSH) measured. (L) qPCR analyzed PINK1/PARKIN/RUNX2/OPG/SIRT3 expression. Experimental design: n =3 biological replicates (technical triplicates). Data: mean ± SD. Statistics: one-way ANOVA. (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001).

    Article Snippet: A cohort of 40 male Sprague-Dawley rats (8-week-old, SPF-grade) were randomly allocated into four groups (n = 10/group): Control: PBS vehicle Model: GIOP Mdivi-1: GIOP + 15 mg/kg Mdivi-1 (MedChemExpress, HY-15 886) i.p. every 48 h [ ] SIRT3 agonist: GIOP + 200 mg/kg nicotinamide riboside (MedChemExpress, HY-15 452) p.o. daily [ ] .

    Techniques: Expressing, Quantitative RT-PCR, Western Blot, Multiplex Assay, Staining

    SIRT3 prevents GIOP by regulating mitophagy-dependent ferroptosis (A) Tibial sections were co-stained for FTH/GPX4 and RUNX2/OPG (scale bar = 500 μm). (B) Intracellular ROS levels were visualized by fluorescence staining (scale bar = 1000 μm). (C) Mitophagy markers PINK1/PARKIN were co-localized by IF (scale bar = 100 μm). (D) Micro-CT reconstructed 2D trabecular architecture. (E) Histomorphometric analysis of bone structure (HE staining, scale bar = 200 μm). Experimental design: n =5 biological replicates/group. Data presented as mean ± SD. Statistical analysis: two-tailed Student’s t-test. (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001)

    Journal: International Journal of Surgery (London, England)

    Article Title: Targeting SIRT3 to regulate mitophagy-dependent ferroptosis for preventing glucocorticoid-induced osteoporosis

    doi: 10.1097/JS9.0000000000002783

    Figure Lengend Snippet: SIRT3 prevents GIOP by regulating mitophagy-dependent ferroptosis (A) Tibial sections were co-stained for FTH/GPX4 and RUNX2/OPG (scale bar = 500 μm). (B) Intracellular ROS levels were visualized by fluorescence staining (scale bar = 1000 μm). (C) Mitophagy markers PINK1/PARKIN were co-localized by IF (scale bar = 100 μm). (D) Micro-CT reconstructed 2D trabecular architecture. (E) Histomorphometric analysis of bone structure (HE staining, scale bar = 200 μm). Experimental design: n =5 biological replicates/group. Data presented as mean ± SD. Statistical analysis: two-tailed Student’s t-test. (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001)

    Article Snippet: A cohort of 40 male Sprague-Dawley rats (8-week-old, SPF-grade) were randomly allocated into four groups (n = 10/group): Control: PBS vehicle Model: GIOP Mdivi-1: GIOP + 15 mg/kg Mdivi-1 (MedChemExpress, HY-15 886) i.p. every 48 h [ ] SIRT3 agonist: GIOP + 200 mg/kg nicotinamide riboside (MedChemExpress, HY-15 452) p.o. daily [ ] .

    Techniques: Staining, Fluorescence, Micro-CT, Two Tailed Test

    Fig. 5 SIRT3 exerts its regulatory role by modulating mitophagy. a Firstly, ferroptosis and mitochondria-related proteins were selected from public databases and intersected with the differentially expressed proteins obtained from bone slices of SIONFH patients. A total of 45 proteins were identified from patient samples. Finally, the key protein SIRT3 was determined using Lasso, random forest (RF), and support vector machine with recursive feature elimination (SVM-RFE) methods. b WB analysis of SIRT3 expression in MC3T3-E1 cells treated with DEX. c IF staining of SIRT3 expression in MC3T3-E1 cells treated with DEX. Scale bar = 50 μm. d Molecular docking was performed to predict the interaction between SIRT3 and BNIP3. e Co-IP was performed to investigate the interaction between SIRT3 and BNIP3. f Effect of SIRT3 agonist on the proliferation of MC3T3-E1 cells was determined by CCK-8 assay after 2 days of stimulation. g Assessment of mitophagy levels using TEM after DEX and SIRT3 agonist intervention. For regular images, scale bar = 50 μm, and for magnified images, scale bar = 10 μm. h IF staining of SIRT3, BNIP3, NIX and DRP1 expression in MC3T3-E1 cells treated with DEX and SIRT3 agonist. Scale bar = 50 μm. i WB analysis of SIRT3, BNIP3, NIX, DRP1, MFN1 and MFN2 expression in MC3T3-E1 cells treated with DEX and SIRT3 agonist. j Flow cytometry analysis of ROS using MFI after DEX and SIRT3 agonist intervention. k The evaluation MMP was performed using JC-1 staining following DEX and SIRT3 agonist intervention. Scale bar = 200 μm. In the DEX + SIRT3 agonist group, 1 μmol/L DEX and 800 μmol/L SIRT3 agonist was added. The cell sample size is n = 3. Data were shown as mean ± SD. One-way ANOVA with Bonferroni multiple comparisons test was used for multiple comparisons. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.000 1

    Journal: Bone research

    Article Title: Isovitexin targets SIRT3 to prevent steroid-induced osteonecrosis of the femoral head by modulating mitophagy-mediated ferroptosis.

    doi: 10.1038/s41413-024-00390-0

    Figure Lengend Snippet: Fig. 5 SIRT3 exerts its regulatory role by modulating mitophagy. a Firstly, ferroptosis and mitochondria-related proteins were selected from public databases and intersected with the differentially expressed proteins obtained from bone slices of SIONFH patients. A total of 45 proteins were identified from patient samples. Finally, the key protein SIRT3 was determined using Lasso, random forest (RF), and support vector machine with recursive feature elimination (SVM-RFE) methods. b WB analysis of SIRT3 expression in MC3T3-E1 cells treated with DEX. c IF staining of SIRT3 expression in MC3T3-E1 cells treated with DEX. Scale bar = 50 μm. d Molecular docking was performed to predict the interaction between SIRT3 and BNIP3. e Co-IP was performed to investigate the interaction between SIRT3 and BNIP3. f Effect of SIRT3 agonist on the proliferation of MC3T3-E1 cells was determined by CCK-8 assay after 2 days of stimulation. g Assessment of mitophagy levels using TEM after DEX and SIRT3 agonist intervention. For regular images, scale bar = 50 μm, and for magnified images, scale bar = 10 μm. h IF staining of SIRT3, BNIP3, NIX and DRP1 expression in MC3T3-E1 cells treated with DEX and SIRT3 agonist. Scale bar = 50 μm. i WB analysis of SIRT3, BNIP3, NIX, DRP1, MFN1 and MFN2 expression in MC3T3-E1 cells treated with DEX and SIRT3 agonist. j Flow cytometry analysis of ROS using MFI after DEX and SIRT3 agonist intervention. k The evaluation MMP was performed using JC-1 staining following DEX and SIRT3 agonist intervention. Scale bar = 200 μm. In the DEX + SIRT3 agonist group, 1 μmol/L DEX and 800 μmol/L SIRT3 agonist was added. The cell sample size is n = 3. Data were shown as mean ± SD. One-way ANOVA with Bonferroni multiple comparisons test was used for multiple comparisons. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.000 1

    Article Snippet: The SIRT3-agonist group received a daily oral gavage of 200mg/kg SIRT3 agonist59 (Nicotinamide riboside chloride, MedChemExpress).

    Techniques: Plasmid Preparation, Expressing, Staining, Co-Immunoprecipitation Assay, CCK-8 Assay, Flow Cytometry

    Fig. 6 SIRT3 inhibits ferroptosis and restores osteogenic capacity by regulating mitophagy. a IF staining and b WB analysis of GPX, FTH and TFR expression in MC3T3-E1 cells treated with DEX and SIRT3 agonist. Scale bar = 50 μm. c Measurement of MDA, Fe2+, and GSH content in MC3T3-E1 cells following DEX and SIRT3 agonist intervention. d ALP staining and e WB analysis of RUNX, OCN, and OPG expression in the MC3T3-E1 cells treated with DEX and SIRT3 agonist. In the DEX + SIRT3 agonist group, 1 μmol/L DEX and 800 μmol/L SIRT3 agonist were added. The cell sample size is n = 3. Data were shown as mean ± SD. One-way ANOVA with Bonferroni multiple comparisons test was used for multiple comparisons. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.000 1

    Journal: Bone research

    Article Title: Isovitexin targets SIRT3 to prevent steroid-induced osteonecrosis of the femoral head by modulating mitophagy-mediated ferroptosis.

    doi: 10.1038/s41413-024-00390-0

    Figure Lengend Snippet: Fig. 6 SIRT3 inhibits ferroptosis and restores osteogenic capacity by regulating mitophagy. a IF staining and b WB analysis of GPX, FTH and TFR expression in MC3T3-E1 cells treated with DEX and SIRT3 agonist. Scale bar = 50 μm. c Measurement of MDA, Fe2+, and GSH content in MC3T3-E1 cells following DEX and SIRT3 agonist intervention. d ALP staining and e WB analysis of RUNX, OCN, and OPG expression in the MC3T3-E1 cells treated with DEX and SIRT3 agonist. In the DEX + SIRT3 agonist group, 1 μmol/L DEX and 800 μmol/L SIRT3 agonist were added. The cell sample size is n = 3. Data were shown as mean ± SD. One-way ANOVA with Bonferroni multiple comparisons test was used for multiple comparisons. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.000 1

    Article Snippet: The SIRT3-agonist group received a daily oral gavage of 200mg/kg SIRT3 agonist59 (Nicotinamide riboside chloride, MedChemExpress).

    Techniques: Staining, Expressing